



## **Idera Pharmaceuticals to Present Preclinical Data of its Toll-Like Receptor - Targeted Compounds at AACR Meeting**

**April 9, 2008 12:02 PM EDT**

CAMBRIDGE, Mass., Apr 09, 2008 (BUSINESS WIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced that preclinical data from its Toll-Like Receptor (TLR) programs will be presented at the 2008 Annual Meeting of the American Association for Cancer Research (AACR) being held in San Diego, CA, April 12-16, 2008.

Monday, April 14, 8:00AM-12:00PM (PDT): Immune Modulation 1 Session

Abstract 2094 entitled "Preclinical antitumor studies of RNA-based agonists of TLR7 and 8" will be presented by Idera. In the study, TLR7 and 8 agonists were evaluated for antitumor activity in preclinical mice models.

Abstract 2078 entitled "Antitumor activity of IMO-2055, an agonist of TLR9, in combination with erlotinib and bevacizumab in non-small cell lung cancer xenografts in mice" will be presented by Idera. In the study, IMO-2055, a TLR9 agonist, was evaluated in combination with erlotinib and bevacizumab in preclinical mice models.

Tuesday, April 15, 4:25PM-4:40PM (PDT): Developmental Immunotherapy Session

Abstract 4994 entitled "TLR9 agonists enhance the efficacy of cancer vaccines" will be presented by researchers from Merck & Co., Inc., the Company's collaborator for vaccine adjuvants.

About Idera Pharmaceuticals, Inc.

Idera Pharmaceuticals develops drug candidates to treat infectious diseases, autoimmune diseases, cancer, and respiratory diseases, and for use as vaccine adjuvants. Our proprietary drug candidates are designed to modulate specific Toll-like Receptors, which are a family of immune system receptors that direct immune system responses. Our pioneering DNA and RNA chemistry expertise enables us to create drug candidates for internal development and generates opportunities for multiple collaborative alliances. For more information, visit [www.iderapharma.com](http://www.iderapharma.com).

### **Idera Forward Looking Statements**

This press release contains forward-looking statements concerning Idera Pharmaceuticals, Inc. that involve a number of risks and uncertainties. For this purpose, any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "estimates," "intends," "should," "could," "will," "may," and similar expressions are intended to identify forward-looking statements. There are a number of important factors that could cause Idera's actual results to differ materially from those indicated by such forward-looking statements, including whether products based on Idera's technology will advance into or through the clinical trial process on a timely basis or at all and receive approval from the United States Food and Drug Administration or equivalent foreign regulatory agencies; whether, if the Company's products receive approval, they will be successfully distributed and marketed; whether the Company's collaborations with Novartis, Merck & Co., and Merck KGaA will be successful; whether the patents and patent applications owned or licensed by the Company will protect the Company's technology and prevent others from infringing it; whether Idera's cash resources will be sufficient to fund the Company's operations; and such other important factors as are set forth under the caption "Risk Factors" in Idera's Annual Report on Form 10-K filed on March 11, 2008, which important factors are incorporated herein by reference. Idera disclaims any intention or obligation to update any forward-looking statements.

SOURCE: Idera Pharmaceuticals, Inc.

Idera Pharmaceuticals, Inc.

Kelly Luethje, 617-679-5519

[kluethje@iderapharma.com](mailto:kluethje@iderapharma.com)

or

MacDougall Biomedical Communications

Chris Erdman, 781-235-3060

[cerdman@macbiocom.com](mailto:cerdman@macbiocom.com)